Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA reports a fourth-quarter 2025 earnings and revenue beat as margins expanded and full-year adjusted EPS rose by double digits.
DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
DaVita HealthCare (DVA) came out with quarterly earnings of $3.4 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $2.24 per share a year ago.
DaVita projected annual profit above estimates on Monday after reporting better-than-expected fourth-quarter results on steady demand for its kidney dialysis services, sending its shares up 13% in after-hours trading.
DVA's fourth-quarter 2025 performance is likely to have gained from technology upgrades, cost control and seasonal boosts despite ongoing volume headwinds.
DaVita HealthCare (DVA) concluded the recent trading session at $105.61, signifying a -1.77% move from its prior day's close.
In the latest trading session, DaVita HealthCare (DVA) closed at $106.3, marking a +2.28% move from the previous day.
DVA stock benefits from a patient-centric model, third-quarter revenue growth and overseas expansion, though reliance on commercial payers remains a risk.
DaVita HealthCare (DVA) closed the most recent trading day at $104.47, moving 5.11% from the previous trading session.
DaVita HealthCare (DVA) reached $111.01 at the closing of the latest trading day, reflecting a -3.23% change compared to its last close.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $116.51, denoting a +1.14% move from the preceding trading day.